RT-01
Showing 1 - 25 of 5,110
T-cell Lymphoma, Virus, Intravenous Injection Trial (Oncolytic Virus Injection(RT-01))
Not yet recruiting
- T-cell Lymphoma
- +2 more
- Oncolytic Virus Injection(RT-01)
- (no location specified)
May 18, 2022
Advanced Solid Tumor Trial in Xuzhou (Oncolytic Virus Injection(RT-01))
Recruiting
- Advanced Solid Tumor
- Oncolytic Virus Injection(RT-01)
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
May 4, 2022
Solid Tumor, Advanced Cancer Trial in Wuxi (Oncolytic Virus Injection(RT-01))
Recruiting
- Solid Tumor
- Advanced Cancer
- Oncolytic Virus Injection(RT-01)
-
Wuxi, Jiangsu, ChinaWuxi People's Hospital
Jan 19, 2022
Advanced Solid Tumor Trial in Wuxi (Oncolytic Virus Injection (RT-01))
Recruiting
- Advanced Solid Tumor
- Oncolytic Virus Injection (RT-01)
-
Wuxi, Jiangsu, ChinaWuxi People's Hospital
Jan 19, 2022
Healthy Volunteer Trial in Prahran (Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI),
Completed
- Healthy Volunteer
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
- Vardenafil Oral Tablet
-
Prahran, Victoria, AustraliaNucleus Network, Burnet Institute
Nov 2, 2022
Skin Cancer, Non-Melanoma Trial (Surgery with additional moderate hypofractionation RT (15 fractions), Surgery alone, without
Not yet recruiting
- Skin Cancer, Non-Melanoma
- Surgery with additional moderate hypofractionation RT (15 fractions)
- +2 more
- (no location specified)
Mar 20, 2023
Pulmonary Arterial Hypertension Trial in Darlinghurst, Hobart, Melbourne (Drug: RT234 - vardenafil inhalation powder; Device:
Completed
- Pulmonary Arterial Hypertension
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
-
Darlinghurst, New South Wales, Australia
- +2 more
Apr 20, 2022
Extensive-stage Small-cell Lung Cancer Trial in Sydney, Brisbane, Melbourne (Radiotherapy, Chemotherapy)
Recruiting
- Extensive-stage Small-cell Lung Cancer
- Radiotherapy
- Chemotherapy
-
Sydney, New South Wales, Australia
- +6 more
Mar 21, 2023
Anal Cancer Trial run by the NCI (Tempol, 5-Fluorouracil, Mitomycin-C)
Terminated
- Anal Cancer
- Tempol
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 25, 2021
Carcinosarcoma, Endometrial Tumors Trial in United Kingdom (Paclitaxel, Cediranib, Olaparib)
Active, not recruiting
- Carcinosarcoma
- Endometrial Neoplasms
- Paclitaxel
- +2 more
-
Northwood, Middlesex, United Kingdom
- +14 more
Feb 10, 2022
HPV Positive Oropharyngeal Squamous Cell Carcinoma Trial in Australia, New Zealand (Cetuximab, RT (70 Gy in 35 fractions),
Active, not recruiting
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Cetuximab
- +2 more
-
Canberra, Australian Capital Territory, Australia
- +15 more
Feb 7, 2021
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed Trial in United States (RQ-001, Placebo)
Recruiting
- COVID-19
- +3 more
- RQ-001
- Placebo
-
Cullman, Alabama
- +8 more
Sep 28, 2023
Eczema, Atopic Dermatitis Trial in Worldwide (KY1005, Placebo)
Active, not recruiting
- Eczema
- Atopic Dermatitis
- KY1005
- Placebo
-
Fremont, California
- +102 more
Dec 13, 2022
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy Trial
Not yet recruiting
- Hepatocellular Carcinoma
- +3 more
- (no location specified)
Feb 21, 2023
Gene Signatures Searching of Sensitivity/Resistance to
Recruiting
- Soft Tissue Sarcomas
- pre-operative radiation
- Standard surgery after rpreoprative radiation
-
Lyon, FranceCentre Léon Bérard
Feb 20, 2023
Tumor Recurrence Following Radiotherapy
Recruiting
- Prostate Cancer
-
Rochester, MinnesotaMayo Clinic
Jan 20, 2023
Glioblastoma Multiforme, Adult Trial (Adaptive, two-phase RT)
Not yet recruiting
- Glioblastoma Multiforme, Adult
- Adaptive, two-phase RT
- (no location specified)
Feb 8, 2023
Improving Outcomes for Older Adults Undergoing Radiation Therapy
Recruiting
- Cancer
- Radiation Therapy
-
New York, New YorkOne Gustave L Levy Place
Jan 31, 2023
Atopic Dermatitis Trial in Worldwide (ZPL389 30mg, ZPL389 50mg, TCS and/or TCI)
Terminated
- Atopic Dermatitis
- ZPL389 30mg
- +2 more
-
Litchfield Park, Arizona
- +47 more
Oct 7, 2021
Breast Cancer, Radiation Toxicity Trial in Ghent (Radiotherapy)
Completed
- Breast Cancer
- Radiation Toxicity
- Radiotherapy
-
Ghent, Oost-Vlaanderen, Belgium
- +1 more
Jan 3, 2023
Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With
Recruiting
- Idiopathic Anosmia
- +2 more
- RT-QuiC
-
Copenhagen, Denmark
- +1 more
Feb 22, 2023
CEA mRNA in Smog and Tissue Exudate Whole Process Collected
Recruiting
- Gastric Cancer
- Radical Gastric Cancer Surgery
-
Qingdao, Shandong, ChinaThe Affiliated Hospital of Qingdao University
Oct 7, 2023
Glioblastoma Multiforme Trial in Toronto (Reduced margin adaptive radiotherapy)
Recruiting
- Glioblastoma Multiforme
- Reduced margin adaptive radiotherapy
-
Toronto, Ontario, CanadaSunnybrook Health Sciences Centre
Oct 19, 2022
Radiomics-based Malnutrition for Cervical Cancer.
Not yet recruiting
- Cervical Cancer
- Malnutrition
- There are no interventions.
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Jan 24, 2023